Tolerx, Inc.

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy in Phase 3 development for type 1 diabetes, for which Tolerx is partnered with GlaxoSmithKline. A second clinical product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for cancer. TRX1, a third immunotherapy candidate, is an anti-CD4 antibody that has been clinically evaluated for the treatment of aberrant or untoward immune responses. The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and are being evaluated for potential benefit in the treatment of cancer and chronic viral infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.